Clinical Trials Directory

Trials / Terminated

TerminatedNCT05088876

Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control

Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control - a Randomized, Double-blind, Placebo-controlled, Non-inferiority Study

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
7 (actual)
Sponsor
Insel Gruppe AG, University Hospital Bern · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Blinded withdrawal of regular co-medication with paracetamol in chronic pain patients under strong opioids on pain control.

Detailed description

Chronic pain patients receiving a strong opioid in combination with paracetamol in a minimum dose of 1.5 g/day will be randomized to receive either paracetamol in the dose already prescribed (group "paracetamol") or an identically looking placebo (group "placebo") using the same schedule during the first study phase (days 1-7). In the second study phase (days 8-14) paracetamol or placebo will be stopped in both arms to assess the effect of pill withdrawal on pain control. Next to baseline the patients will be instructed to use a pain diary to rate their pain during the study and also document the required opioid rescue doses. Further assessments will include adverse events, subjective ratings of quality of sleep, overall feeling of functioning and quality of life. At the screening visit, patients will also be asked to rate their expected changes in pain relief as a result of co-treatment with paracetamol. At the completion of the study, patients will be asked about their preference and whether, overall, they felt their pain was more poorly controlled during the study. Adherence will be checked by pill count and measurement of paracetamol blood concentrations. Genotyping of OPRM1, COMT and relevant CYP enzymes and opioid blood concentrations will be assessed as co-variates for pain control.

Conditions

Interventions

TypeNameDescription
DRUGPlaceboBlinded withdrawal of regular co-medication with paracetamol
DRUGParacetamolParacetamol in the dose already used

Timeline

Start date
2024-08-28
Primary completion
2026-03-05
Completion
2026-03-05
First posted
2021-10-22
Last updated
2026-04-13

Locations

2 sites across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT05088876. Inclusion in this directory is not an endorsement.

Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control (NCT05088876) · Clinical Trials Directory